Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease

Numab Therapeutics AG and Kaken Pharmaceutical Co., Ltd. announced a new collaboration and option agreement to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease.